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1. Introduction 
From the establishment of etiologic relationship between HPV and cervical cancer, 
researchers have emphasized the importance of prevention by education of people, 
especially teenagers. This virus is associated with diseases of the cutaneous and mucosal 
human epithelia, including benign warts and invasive cancer that affect different anatomical 
regions as skin, cervix, vagina, vulva, anus, penis, head and neck. Controversial evidence 
suggests a relationship between HPV infection and breast cancer (de Villiers et al., 2005; 
Khan et al., 2005; Heng et al., 2009) (Table 1). 
 
Clinical manifestation HPV types often detectable 
Verrucae vulgares, verrucae palmares et plantares 1, 2, 4 
Verrucae planare 3, 10 
Butcher´s warts 7 
Squamous cell carcinoma of the finger, Bowen´s disease 16 
Epidermodysplasia verruciformis (EV) 3, 5, 8 
EV- squamous cell carcinoma 5, 8 
Condylomata acuminata 6, 11 
High grade-squamous intraepithelial neoplasias and invasive 
carcinomas of the anogenital tract 
16 
Bowenoid papulosis, erythroplasia of Queyrat 16 
Buschke-Lowenstein tumor 6, 11 
Respiratory Papillomatosis 6, 11 
Heck´s disease 13, 32 
Head and neck cancers (larynx, tonsils, tongue, sinuse, lung) 16, 18, 6, 11 
Breast cancer? 16, 18 
Table 1. Clinical manifestations and associated HPV types (taken and modified of 
Handisurya et al., 2009).  
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Noted that a variety of diseases caused by HPV is largely due to viral tropism, i.e., the 
preference of a certain type of HPV by a tissue or cell group in particular, depending on 
factors of virus and host, mainly receptors, transcriptional activators, enhancers, and tissue-
specific promoters (Graham, 2010). Based on the tropism, HPV has been classified into two 
main phylogenetic genera, the ┙-HPV and the ┚-HPV, which correspond to the   mucosal 
and cutaneous infective HPV, respectively (de Villiers et al., 2004). The temporal 
organization of the virus replication cycle is also different between different HPV types 
perhaps reflecting differences in sites of infection and transmission modes. 
Traditionally, cancer and associated lesions have been treated with surgery, radiotherapy 
and chemotherapy, these  treatments produced widely known adverse effects (American 
Cancer Society, 2007; Instituto Nacional del Cáncer, 2008).  However, many efforts have 
been done in order to find effective preventive and curative options less invasive and with 
minimal or no side effects. These options are mainly based on molecular biology techniques 
to develop  vaccines and the use of molecules that stimulate the immune  and cytotoxic 
response against HPV infection and cervical cancer. The development of these vaccines and 
therapeutic procedures is based on in vitro culture and knowledge of the life cycle, genome 
and regulation of viral transcription, which has allowed the identification of potential 
targets to control genes expression in infectious and / or neoplastic processes (Table 2). 
 
Genome 
region 
Gen/ 
protein 
Expression 
site 
Function 
Early 
E1 
Basal, 
parabasal 
and 
intermedia
te cells of 
the host 
ATP- dependent DNA helicase; unique enzyme 
expressed by the virus, which is essential for 
viral replication 
E2 
Helps E1 to locate the origin of replication in 
LCR, cell cycle and apoptosis regulation 
E4 
Cell Cycle arrest, virion assembly, remodels 
cytokeratin network 
E5 
Control of cell growth and differentiation, 
immune modulation 
E6 Inhibits apoptosis and differentiation 
E7 
Cell cycle control, controls centrosome 
duplication 
Late 
L1 
Superficial 
cells 
Major capsid protein 
L2 
Minor capsid protein, recruits L1, virus 
assembly 
Long control 
region (LCR) 
  
Binds many cellular transcription activators, 
confers keratinocyte specificity to transcription 
Table 2. Role of HPV genome regions  
2. Prophylactic vaccines to prevent HPV infection 
Prophylactic vaccines currently exist to prevent the spread of HPV infections; these vaccines 
have the objective to create antigens capable to induce neutralizing antibodies that prevent 
the entry of virus into host cells.  They are based on preventing infection of HPV types most 
prevalent around the world: types 6 and 11, of low oncogenic risk, associated with the 
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formation of warts and benign condylomata, and types 16 and 18 of high cancer risk, 
associated with cancerous and precancerous lesions, which are responsible for 
approximately 70% of all cervical cancers worldwide (Muñoz et al., 2004).Initially it was 
suggested to produce a vaccine based on attenuated virus, but its implementation and 
evaluation in humans was a very high risk due to the presence of oncogenic viral DNA; in 
addition  the growth of virus in in vitro culture had been limited until recently when a 
researchers  group managed to establish a reproducible and highly efficient production of 
HPV type 18 in human keratinocytes, which has a potential value for establishing research 
models of ex vivo viral expression (Castellsagué et al., 2006; Wang et al., 2009). 
Moreover, although the studies on the immunology of HPV have shown antibodies against 
many different viral products, the best characterized and most type-specific antibodies are 
those directed against conformational epitopes of the L1 capsid protein. In the 90's it was 
possible to produce in vitro, genetically engineered virus-like particles or VLPs, which 
consist of L1 or L1 + L2 recombinant protein, obtained by introducing one or both genes, 
respectively, in cultures of eukaryotic cells (yeast, insect or bacteria). These recombinant 
proteins have the ability to self-assemble to form three-dimensional structures that are 
morphological and antigenically identical to the original HPV virions, but not containing the 
viral genome, so these structures can not replicate or cause infection or cancer (Muñoz et al., 
2008).  
There have been studies in experimental animal models and humans, where there was a 
good tolerance to systemic vaccination with L1- VLPs, and induction of serum antibody 
titers of at least 40 times higher than the titles produced in an natural infection (Lowy & 
Frazer, 2003). The first large multicenter, double-blind study, with phase III results, was 
published in 2002, on a monovalent vaccine developed by Merck Laboratories HPV type 16 
(Brull & Carrera, 2005). This company created another quadrivalent  vaccine called Gardasil,  
synthesized in the yeast Saccharomyces cerevisiae, based on L1- VLPs of oncogenic types most 
commonly found in cervical dysplasia (HPV types 16 and 18) and non-oncogenic types 
responsible for approximately 90% of warts genitals and recurrent respiratory 
papillomatosis (types 6 and 11), which is considered to act on two different 
hyperproliferative diseases (Schiller & Lowy, 2006). It was approved by the U.S. Food and 
Drug Administration (FDA) in 2006 and is administered in 3 doses, spread over 6 months (0, 
2 and 6 months). Follow-up studies for 3 ½ years after vaccination showed an effectiveness 
of 94% in persistent infection with HPV types 16, as well as 100% in preventing high-grade 
intraepithelial lesions associated with types 16 and 18, and prevention of genital lesions 
related to HPV types 6 and 11 (Mao et al., 2006; Villa et al., 2005). The efficacy against vulvar 
and vaginal neoplasia grade II and III was 72-100% (Joura et al., 2007). In well designed 
clinical trials in young women aged 15-25 years who were HPV 16/18 seronegative and 
DNA negative to 14 HPV high-risk types, high levels of immunogenicity and protection 
were sustained for follow-up periods of up to 8.4 years (McKeage & Romanowski, 2011). 
Each 0.5-mL dose contains 20 µg HPV 6 L1 protein, 40 µg HPV 11 L1 protein, 40 µg HPV 16 
L1 protein, and 20 µg HPV 18 L1 protein. VLPs are adsorbed on an aluminum-containing 
adjuvant. Each 0.5-mL dose contains 225 µg amorphous aluminum hydroxyphosphate 
sulfate. The formulation also includes sodium chloride, L-histidine, polysorbate 80, sodium 
borate, and water for injection. The quadrivalent HPV vaccine contains no thimerosal or 
antibiotics. The vaccine should be stored at 2°C--8°C (36°F--46°F) and not frozen.  
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
180 
GlaxoSmithKline laboratories developed a bivalent vaccine called Cervarix for HPV types 16 
and 18, produced in insect cells with baculovirus as expression system, which is also 
administered in three doses (0, 1 and 6 months). Studies reported 100% efficacy in 
preventing infections with involved HPV types, with an almost absolute immunogenicity 
for 4 ½ years after vaccination and the detection of antibody titers from 16 to 26 times higher 
than detected after natural infection (McKeage & Romanowski, 2011; Bhatla et al., 2010; 
Muñoz et al., 2008; Harper et al., 2004; Kahn, 2005).  
Both vaccines (Gardasil and Cervarix) use aluminum-based adjuvants, which reduces the 
dose required to induce antibodies peak titer and helps to stabilize the vaccine during 
storage (Schiller & Lowy, 2006). Overall adverse effects reported in vaccination protocols are 
limited and include reactions at the injection site (erythema, pain and swelling) and 
systemic adverse effects (headache, fever and nausea) which were of middle nature, 
transitory and common for individuals receiving the vaccine or placebo (Paavonen et al., 
2007). 
Whereas the onset of sexual activity during adolescence, the FDA approved the vaccine 
Gardasil for girls and women aged between 9 to 26 years, while the Advisory Committee on 
Immunization Practices of the USA Center for Disease Control and Prevention (ACIP) 
recommended vaccination in females aged between 11 to 26 years and added males to the 
population who can benefit from Gardasil vaccination (FDA,  2010). 
There has been controversy regarding the vaccination of women alone or the inclusion of 
men. In this regard, it has been noted that vaccinating girls aged 12 years old, can reduce 
cases of cervical cancer associated with types 16 and HPV 18 in about 95% and the 
introduction of vaccination in children would increase this figure three points (Taira et al., 
2004). We must also take into account the potential role of vector that man can exert on the 
transmission of HPV infection, so the inclusion of the male population in vaccination 
programs could contribute to optimal control of transmission (Tirado-Gómez et al., 2005). 
Currently the vaccine is not recommended for pregnant women. The long-term effects of the 
vaccine on fertility are not known, but no effects are anticipated. Although studies on the 
toxicity to the fetus are inconclusive, FDA has classified the HPV vaccine as a pregnancy 
Category B medication, meaning that the medication does not appear to cause harm to the 
fetus in animal studies. Initially, the trials for Gardasil and Cervarix excluded pregnant 
women. Pregnancy was determined by a sensitive human chorionic gonadotropin (HCG) 
test on the day of expected vaccination. However, some women became pregnant during the 
few weeks or months following the receipt of a vaccine or placebo injection. Overall, the 
proportions of pregnancies with an adverse outcome were comparable in subjects who 
received Gardasil and subjects who received placebo. However, the clinical trials had a 
relatively small sample size. Though receiving the HPV vaccine while pregnant is generally 
considered safe, it is still recommended to wait until after pregnancy to get the vaccine 
(American Cancer Society, 2008).  
Vaccination at early age has led to concerns of parents, researchers and health specialists 
because of the need to talk with children about sexuality and sexually transmitted diseases, 
the vaccination charges received by children, the possibility that immunization may lead to 
the adoption of risky sexual behaviors and concerns about the safety of vaccines (Kahn, 
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2005).  Some researchers have pointed out as risk of vaccination the possible selection of not 
included HPV types in vaccines or the increase in the prevalence of rare oncogenic HPV 
types, which can only be known over time, after the mass vaccination had been effective.  
Other weaknesses of the prophylactic vaccine against HPV is that it only protects against 
specific HPV types, leaving out a wide range of viral types, although rare, are also present, 
and have also been reported conflicting results regarding the existence of cross protection. 
In addition, the vaccine is preventive (not cure existing infections or injuries) and there is a 
low percentage of cervical cancer and precursor lesions in which no association has been 
established with HPV, existing other factors associated with the development of this 
malignancy, as exposure to mutagens, genetic susceptibility, hormonal status and immune 
status (Tirado-Gómez et al., 2005; del Amo et al., 2005); unknown the duration of protection 
provided by the vaccine, it may be necessary to administer a booster dose (Brull & Carrera, 
2005; Diestro Tejeda et al., 2007). In this regard, an  evaluation  showed that the quadrivalent 
vaccine provides strong and sustained protection against condiloma and vulvovaginal and 
cervical low grade neoplasia, related to types 6, 11, 16 and 18, for more than four years. The 
same study suggests that the effectiveness of the vaccine might be less in cases where 
coinfection with HPV types absent in the vaccine is present (Dillner, 2010). 
It is important to take into account the high cost of the vaccines listed, however, this is not 
comparable to the loss of life or money spending for the treatments of lesions associated 
with HPV infection. Since vaccines are prophylactic and only provide preventive (no 
therapeutic) effect, most benefits are gained by vaccinating before infection occurs, ideally 
before the onset of sexual intercourse. In this sense, the ACIP has recommended the 
introduction of HPV vaccine in national immunization programs of governments 
worldwide. It is therefore essential to determine the HPV types circulating in each region 
and assess the potential impact of preventive vaccination in the respective populations. 
Various researchers have emphasized that even with the globalization of preventive 
vaccination, screening schemes should continue due to multifactorial nature of cervical 
cancer, only 2 of 15 oncogenic HPV types are included in the vaccine and vaccination 
programs initially cover women into a limited range of ages, anticipating that at least during 
2-3 decades unvaccinated sexually active women remain at risk for the disease (Giuliano, 
2007; Stanley, 2008; Hutchinson & Klein, 2008). 
The efficacy of L2 vaccination has been proved in pre-clinical and clinical studies. Natural 
infection does not induce anti-L2 antibodies and many L2 epitopes are not on the virus 
surface, but during the infection cellular protease furin removes an L2 N-terminal sequence 
rendering L2 accessible on the capsid surface and displaying the L2-neutralizing epitopes. 
The L2-neutralizing epitope was inserted on the surfaces of VLPs increasing the titers of  
neutralizing antibodies approximately 10-fold. A synthetic L2 lipopeptide with 
concatenated multitype L2 fusion proteins from different papillomavirus types have already 
been utilized in inducing cross-neutralizing antibodies against several clinically relevant 
HPV types. This polymeric L2 approach gives rise to antisera, that neutralize at higher titers, 
not only the types included in the multimeric immunogen but also other types. So, 
immunization against L2 could be a candidate prophylactic pan-human papillomaviruses 
vaccine (Alphs et al., 2008; Jagu et al., 2009).  
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3. Therapeutic vaccines and gene therapy for treatment of cervical cancer 
Another line in the study of cervical cancer treatment has pursued in the implementation of 
therapeutic vaccines and / or gene therapy to cure existing cases, through the transfer of 
DNA, inserting the normal gene or gene expression regulation.  
Therapeutic vaccines are composed of peptides homologous to the viral proteins, as 
indicated in the treatment of dysplasia and invasive cervical cancer or as adjuvant therapy 
for locally recurrent or metastatic (Diestro Tejada et al., 2007). DNA vaccines have also been 
developed, which are considered as stable, safe, can be prepared in large quantities and 
repeatedly administered without significant adverse effects. In addition, the DNA tends to 
be preserved in the receptor cells, ensuring long-term expression of the encoded antigen and 
reinforcing the maintenance of immunological memory.  
Generally, the immune response generated from DNA alone is weak, so it has been tested 
the adjuvant effect of several molecules, and the combination of specific genes (Kim et al., 
2004). However, vaccines have been developed based on naked DNA, viral or bacterial 
vector, tumor cells and dendritic modified cells.  
Other molecules in use for gene therapy of cervical cancer are cytokines which has 
immunoregulatory effect that promotes maturation, activation and migration of effector 
cells of the immune response to the tumor site. Of particular interest are interferons, 
interleukin 2 or IL-2 (which activates T cells, NK cells, macrophages and the release of other 
cytokines) and the aforementioned IL-12 (whose anti-tumor effect individually or in 
combination with E6 and E7 is dependent on the activation of CD8 + cytotoxic T 
lymphocytes and NK cells at the site of immunization). Intratumoral administration of these 
molecules significantly reduced the progression of HPV-associated tumors and inhibited 
recurrent tumor formation after being removed by surgery (Frechtel, 2005; Bubenik et al., 
2003). 
In 1999, a group of researchers developed and tested the vaccine TA-GW based on the L2 
and E7 fusion proteins of HPV type 6, with Alhydrogel as adjuvant, for the treatment of 
condilomas, reporting immunogenicity and cure in approximately 62% of lesions 8 weeks 
after vaccination, without considerables adverse effects (Lacey et al., 1999). 
In 2002, Kaufmann et al. performed one of the first multicenter and multinational studies 
with a recombinant vaccine, TA-HPV, consisting of attenuated vaccinia virus genetically 
engineered to express the E6 and E7 proteins of HPV types 16 and 18. The protocol included 
two doses of the vaccine in patients with early-stage cervical cancer, and the induction of 
humoral and cell-mediated response with low side and/or toxic effects was observed.  
In 2004, Gutierrez et al. evaluated the effect of the recombinant vaccine MVAE2, consisting 
of attenuated vaccinia virus and the E2 gene of HPV, in squamous intraepithelial lesions of 
high and low grade. Treatment consisted in the administration of six doses, one every week, 
injected directly into the cervix. During the observation of treatment results, the reduction of 
injuries was monitored by colposcopy and histological analysis. The immune response was 
determined by measuring of antibodies againts MVAE2 and analysis of cytotoxic 
lymphocyte activity against cancer cells with oncogenic human papillomavirus. The 
presence of viral DNA and viral load were determined using the Hybrid Capture method 
(Digene).  
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After treatment it was possible the elimination of pre-cancerous lesions and even cancer 
(cancer in situ), with an efficiency of 95% in the first and 40% in the latter. All patients 
developed antibodies to the vaccine and a specific cytotoxic response against HPV-
transformed cells. These results were compared with those obtained in a similar group of 
patients treated with cryosurgery, a technique that is able to eliminate low-grade lesions in 
all patients; but there was not observed cytotoxic activity against cancer cells. 
As for of the virus detection, there was no evidence in 50% of the treated sample after 
treatment and in the remaining 50% was only detected 10% of the original viral load. 
Assessments of MVAE2 vaccine in women with cervical cancer are in Phase III, consisting of 
a multicenter study in 250 patients with cancer in situ in the Juarez Hospital of the Ministry 
of Health of Mexico. 
This vaccine was also tested in men for the treatment of urethral condilomas, showing the 
stimulation of the immune response against HPV and regression of lesions in 93% of cases, 4 
weeks after therapy. These assessments are in phase II. The results are promising and show 
that local therapeutic vaccination with MVAE2 is an effective tool for stimulating the 
immune response to HPV infection and the presence of virus-transformed cells, as well as 
regression of high and low grade cancer lesions (Albarran y Carvajal et al., 2007). 
On the other hand, researchers have highlighted the potential utility of gene gun used in the 
administration of DNA-based vaccines as part of the antigenic systems strategy for the 
control of cancer and infectious diseases, projecting itself as an important tool in antigen-
specific immunotherapy (Kim et al., 2008a).  
In the particular case of uterine cancer, Kim et al. (2008b), in a mouse model, used a Helio gun 
to dispense gold microparticles coated with E6 DNA of HPV type 16 attached to an expression 
regulator of major histocompatibility complex  class I molecules (human calreticulin). They 
observed an increased cellular and humoral immune response and antitumor effect, from the 
increased processing and presentation of antigens to T cells, together with the regression of 
tumors, enhanced antigen-specific memory and prolonged survival of vaccinated mice. The 
authors highlight the potential clinical benefits of this therapeutic strategy in humans, which 
may include co-administration of molecules with other properties, e.g. DNA encoding anti-
apoptotic or angiogenic proteins (Kim et al., 2004; Kim et al., 2008b). 
This vaccine was combined with E7 and L2 proteins of HPV, also observed significant 
therapeutic effects against E6/E7 expressing tumor cells, and generate a potent L2-antigen 
specific response, thereby protecting against pseudovirion infection. These results highlight 
the potential clinical benefits of this vaccine (Kim et al., 2008b). 
Ahn et al. (2004) performed in mice, direct intratumoral injection of an adenoviral vaccine 
carrier E7 sequence of HPV type 16 and interleukin 12 (IL-12) as adjuvant, which induces 
cellular immune responses for protection against tumor formation. They observed partial or 
complete regression of the tumors and long-term immunity against recurrence of the 
malignancy, and this effect was much greater with the vaccine formed with the all 
components, compared with the injection of any of the separate components. The IL-12 is one 
of the most widely used cytokine on gene therapy against cervical cancer, due to its effect in 
inhibiting tumor growth and experimental metastasis, dependent on the activation of NK cells.  
However, Sin (2009)  reported that IL-12 and E7 HPV type 16 cDNA-based vaccine lost its 
antitumor and immunoprotective effect when it was combined with nitric oxide (used and 
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known for its adjuvant effect in routine protocols for vaccination), which demonstrates an 
immunosuppressive effect of the compound (nitric oxide) in the system used. 
Peng et al. (2010) in a preclinical model about recurrent respiratory papillomatosis (RRP), 
generated a DNA vaccine that encodes the HPV-11 E6 and E7 genes  in a pcDNA3 backbone 
plasmid. Vaccinated mice generated strong CD8+ T cell response against the E6aa44-51 
peptide, which is presented by the major histocompatibility complex class I molecule. 
Results revealed that the E6aa44-51 peptide contains the most immunogenic region for HPV- 
11 viral type, making it a candidate for the development and evaluation of novel vaccine 
strategies targeting the RRP patient population. 
On the other hand, it has been established that an L1 molecule of various HPV types 
contains several cysteine residues at markedly similar relative positions, strongly suggesting 
that these cysteine residues play important roles in the structure and function of the HPV 
capsids, especially in the viral capsid assembly. Ishii et al. (2007) , in an in vitro model (HeLa 
cells), observed that HPV type 16-pseudovirions lost their infectivity after incubation with 
thiol-reactive reagents that bound to the free thiol of pseudovirions major capsid protein L1, 
due to conformational changes that result in the inhibition of the entry and trafficking of this 
molecules. Therefore, the authors suggest that these reagents might function as practical 
inhibitors of HPV infection. These reagents could be used in drug design or in combination 
with preventive and/or therapeutic strategies.  It would be necessary further evaluation on 
this topic.  
3.1 Antisense molecules and RNA interference in cervical cancer treatment 
Another line of investigation for the treatment of cervical cancer by gene therapy has been 
successful in testing antisense molecules as the ribozyme R434 (which, through its catalytic 
activity, specifically destroys the HPV types 16  E6 and E7 mRNA and prevents the growth 
of immortalized cells in the presence of virus), antisense oligonucleotides (AS-ODN) that 
hybridize with viral messenger blocking viral translation,  and interference RNA (RNAi) 
(Álvarez Salas, 2006; Hamada et al., 1996; Hall & Alexander, 2003) (table 3). 
Both technologies, antisense and RNAi, consist of gene silencing (interruption or 
suppression of the expression of a gene at transcriptional or translational levels).  
Agent Mechanism Result 
Most drugs Bind to target protein Protein inhibition 
RNase H-
independent 
ODNs 
Hybridize to target mRNA 
Inhibition of translation of 
the target protein 
RNase H-
dependent ODNs 
Hybridize to target mRNA 
Degradation of the mRNA 
by RNase H 
Ribozymes and 
DNA enzymes
Catalyze cleavage of target mRNA Degradation of the mRNA 
siRNA 
Hybridize to target mRNA by its 
antisense strand and guide it into 
endoribonuclease enzyme complex 
RISC 
Degradation of the mRNA 
Table 3. Comparison of different gene silencing strategies. 
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The second, based on double-stranded RNA has proven to be more powerful than the first, 
based on single-stranded RNA (Mao et al., 2007).  
The antisense oligonucleotides have shown effectiveness in inhibiting the expression of E6 
and E7 oncogenes, and also produced the release and / or activation of molecules 
involved in defense mechanisms (such as cytochrome c and procaspases 3 and 9), the 
induction of apoptosis and inhibition of telomerase activity. However, it has been 
reported that these molecules are unstable and design and management are very 
expensive (Choo et al., 2000). 
RNA interference (RNAi) is a process of RNA-based gene silencing, which relies on 
nucleotide sequence complementarity and is involved in the mobilization of transposable 
genetic elements, in defense mechanisms and in different cellular events (such as 
differentiation, metabolism , stress response, propagation and apoptosis). This natural RNA-
dependent gene silencing process is controlled by the RNA-induced silencing complex 
(RISC) and is initiated by short double-RNA molecules in a cell´s cytoplasm, where they 
interact with the catalytic RISC component, protein argonauta, and the enzyme Dicer 
(Humayun et al., 2008) (figure 1). 
This process occurs through effector molecules identified in many eukaryotes, called 
microRNAs (miRNAs), highly conserved in orthologous species, indicating their importance 
in basic cellular processes. miRNAs are endogenous short RNA molecules with space-time 
independents expression patterns that determine inhibition of translation or degradation of 
target mRNAs when complementarity is incomplete or perfect, respectively (Raia & Calin, 
2011). Hence, this methodology has a potential therapeutic for various diseases, additionally 
it can be used in the evaluation of molecular and metabolic pathways. MiRNAs originate 
from populations of non-coding small RNAs (they are one of several small non-coding 
RNAs, including ribosomal RNA, transfer RNA and small nuclear RNA) resulting from 
transcription of DNA sequences by RNA polymerase II and form secondary structures 
hairpin loop type. Several investigators have found alterations of these molecules 
(particularly single nucleotide polymorphism or SNP) in all cancers studied to date and 
have indicated that miRNAs are expressed abnormally in these patologies and are involved 
in  predisposition, development  and  progression  of  cancer,   so  they  can  be  used  for 
diagnostic and prognostic purposes. In this regard, miRNAs have been detected in body 
fluids, which favors its use as biomarkers, because their assessment would be less invasive 
compared with other conventional markers, such as Pap smears and biopsies. Also, they can 
become as tumor suppressor, inhibiting cancer development, and as oncogenes, stimulate 
their development, depending on its expression pattern (Patel & Sauter 2011, Vitale et al. 
2011). 
In the biogenesis of mature miRNAs,  act two type III Rnases,  Drosha and Dicer, which cut 
precursor RNAs  in double-stranded RNA (dsRNA)  molecules with a length of 21 to 25 
nucleotides, which will separated to generate single strand molecules (Ketting et al., 2001).  
In addition to miRNAs,  in the RNAi mechanism have also identified other endogenous 
small RNAs called short interfering RNAs (siRNA) which, like miRNAs, originate from 
endogenous complementary dsRNA transcripts, but have an exact length of 21 nucleotides 
and most interesting is that they can derive from mRNA-coding sequences, transposons and 
heterochromatin (Ghildiyal et al., 2008). 
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Fig. 1. A simplified model for the RNAi pathway. 
The model has two steps, each involving ribonuclease enzyme. In the first step, the trigger 
RNA (either dsRNA or miRNA primary transcript) is processed into an short, interfering 
RNA (siRNA) by the RNase II enzymes Dicer and Drosha. In the second step, siRNAs are 
loaded into the effector complex RNA-induced silencing complex (RISC). The siRNA is 
unwound during RISC assembly and the single-stranded RNA hybridizes with mRNA 
target. Gene silencing is a result of nucleolytic degradation of the targeted mRNA by the 
RNase H enzyme Argonaute (Slicer). If the siRNA/mRNA duplex contains mismatches the 
mRNA is not cleaved. Moreover, gene silencing is a result of translational inhibition.  
Source: National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/projects/genome/probe/doc/TechRnai.shtml) 
siRNAs can be designed and artificially synthesized by chemical methods or by molecular 
cloning vectors and have been used to induce gene silencing in vitro and in vivo models, 
showing that perform the same biological functions as the natural miRNAs. The synthetic 
siRNAs can be transfected into mammalian cells by cationic lipofection, where they bind to 
liposomes as transport vehicle. In general, although it has achieved the efficient silencing of 
target genes, this strategy has a high cost and initially required the administration of 
multiple dose in mice, because a considerable percentage of the siRNAs is degraded by the 
action of endogenous endonucleases. Recently, the application of liposomes contained in 
Biogels, has overcome this limitation. The main disadvantage is that synthetic siRNAs have 
a short half-life after application (Sioud & Sorensen, 2003; Jiang et al., 2004). 
It has been suggested that the efficiency of silencing by RNAi not only depends on the 
activity of RISC by itself, but also other factors such as accessibility of RISC to the target 
sequence (which is affected by RNA secondary structure and interaction of target mRNA 
with other molecules) and cleavage and release of cleaved RNA. Moreover, recent studies 
have shown that siRNA has nonspecific effects, ie in addition to its complementary target 
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sequence (Schubert et al., 2005); studies of cervical cancer reported the silencing of the gene 
of interest and the production of inflammatory cytokines and  interferon, simultaneously. 
This was particularly evident when using high concentrations of siRNA. That is the reason 
because the researchers recommend dose-response studies on a given system in order to 
select the lowest concentration of siRNA to observe the desired result, eliminating or 
reducing non-specific responses (Yamato et al., 2008). These nonspecific responses may also 
be caused by mismatches present in a siRNA in a tolerable level with its mRNA target 
(Haley et al., 2004). All these elements must be taken into account to design siRNA 
sequences and protocols in order to obtain the greatest effectiveness and specificity. 
Currently there is software that facilitates the design of these molecules. 
The DNA sequence to silence can also be introduced into a vector that allows the 
transcription of siRNA. These vectors include siRNA expression plasmids, in which the 
DNA insert is placed under the control of the promoter of RNA Pol III (H1 gene or U6 gene) 
and form hairpin secondary structures that are processed by RISC and hybridize to target 
mRNA for its degradation (Brummelkamp et al., 2002).  
Another type of widely used vectors are viruses, because they have a wide capacity of cell 
infection, especially retroviruses and adenoviruses. The former have the ability to integrate 
into the genome of replicating cells and therefore are useful for stable transfection of cancer 
cells. However, it has been reported that the transfection rate is low (de Felipe & Izquierdo, 
2000). Adenoviruses have the ability to infect quiescent cells and dividing cells and produce 
a higher transfection rate than the retroviruses, but are more difficult to handle because of 
the size of its genome (Carette et al., 2004). 
Noted that the use of this technology in the treatment of cervical cancer is possible because 
while E6 and E7 sequester the activities of p53 and pRb proteins in HPV-induced 
malignancies, copies of p53 and pRb wild genes are usually conserved, which confers a 
reversible character of the malignancy, whereas reducing the expression of E6 and E7 in 
HPV-transformed cells could restore the activity of  endogenous tumor suppressor and thus 
prevent the proliferation of these cells (Webster et al., 2000). 
It has also been shown that RNAi technology against E6 and E7 genes induces senescence, 
apoptosis or inhibition of cancer cell growth in cell models (Webster et al., 2000; Butz et al., 
2003; Niu et al., 2006) and destroys or suppresses the growth of tumors in mice injected 
directly with short molecules of RNAi (siRNA) against E6/E7 (Niu et al., 2006; Fujii et al., 
2006). The first work on gene silencing by RNAi in uterine cancer was conducted by Jiang 
and Millner (2002). The researchers, in an in vitro model, administered synthetic siRNAs 
against E6 and E7 oncogenes of HPV 16. They observed the degradation of the E6 and E7 
mRNA, with consequent expression of p53, decreased cell proliferation and induction of cell 
death by apoptosis. In particular, the induction of apoptosis or senescence in tumor cells has 
been effective since the introduction of the transcriptional regulator E2 and the reduction or 
inhibition of  E6 and E7 genes expression (Butz et al., 2003).  
At the molecular level, it was observed that E6 silencing induced accumulation of p53 
cellular protein and transactivation of p21 cell cycle control gene (Jiang & Milner, 2005). On 
the other hand, has been demonstrated the specificity of the technique since it was found 
that E6 RNAi  of HPV type 16  was less efficient in silencing  E6 gene in cells infected with 
other HPV types (Niu et al., 2006). These findings support the usefulness of this technique as 
www.intechopen.com
Human Papillomavirus and Related Diseases  
– From Bench to Bedside – A Clinical Perspective 
 
188 
a tool for investigating the mechanisms involved in the establishment and development of 
malignancy, as for the creation of therapies for treatment and healing. 
It is noteworthy that there are studies that report the simultaneous silencing of E6 and E7, 
while in others there was particular silencing of only one of these oncogenes, when using 
the mechanism of siRNA. It was explained that this is due to the existence of the bicistronic 
E6/E7,  and simultaneous or individual silencing will depend largely on the particulars 
sequences of siRNA used and their positions of complementarity with the target mRNA 
(they may hybridize at a point where affect the expression of both genes or only one). In this 
sense, it has been suggested that alternative splicing events of E6 and E7 oncogenes of HPV 
preced events of silencing by siRNA (Lea et al., 2007). 
Another target in the treatment of cervical cancer with RNAi is the telomerase hTERT gene, 
which has been cloned in several siRNA expression plasmids. This enzyme helps in 
maintaining the genomic stability by synthesizing the telomeres of eukaryotic chromosomes 
to protect them from degradation events, fusion and recombination. Overexpression of this 
enzyme void aging and cell death, as in most somatic cells telomerase activity is very low or 
absent, whereas in undifferentiated or immortal cells is considerable. Using siRNA plasmids 
for hTERT in vivo and in vitro models, it has been observed the target gene silencing, with 
the consequent decrease of telomerase activity, inhibition of cell proliferation, increased 
activity of caspase 3 and death of tumor cells by apoptosis (Wang et al., 2007). 
It has also been observed that the application of siRNA technology increases the sensitivity of 
malignant cells to chemotherapy and radiotherapy. This has been demonstrated with cisplatin 
(study where E6 and E7 oncogenes were silenced), which can then be used in lower 
concentrations with the consequent reduction of its negative effects (Putral et al., 2005).  The 
sensitivity of HeLa cells to radiotherapy increased with the hTERT gene silencing by siRNA, 
which allowed the establishment of a relationship between sensitivity to radiotherapy and 
telomerase activity in this type of cancer (Wang et al., 2007). This observation can be taken into 
account when designing treatment protocols for a given patient. Thus, the combination of 
siRNA with chemotherapy or radiotherapy may be synergistic in reducing cancer resistance to 
conventional therapies, which may promote recovery and / or survival with these therapies. 
4. Conclusions 
While it has been estimated the impact that preventive vaccination may have on the 
transmission of HPV infection and the development of cervical cancer and precursor lesions, is 
important to note the existence of other factors that may affect or influence the development of 
this pathology as well as existing cases prior to vaccination, so the effect of a preventive 
vaccine in the prevalence of cervical cancer may involve several decades. Moreover, 
prophylactic vaccines do not protect against infection (or malignancy) caused by other HPV 
types not contained in them, so cases of disease will still arise and require treatment. 
Faced with these limitations of preventive vaccines, therapeutic vaccines based primarily on 
molecular resources and gene therapy are currently being evaluated and could become as an 
effective tool for the treatment of cervical cancer and low or high grade lesions, contributing 
together to preventive vaccines for a better control of this disease.  
In this regard, studies carried out until to date about the effect of gene therapy on cervical 
cancer, project this technology as an useful and specific tool for the activation of the short 
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and long term immune response, reducing metastasis and regression and even producing 
the elimination of tumors when applied alone or in combination with routine therapies 
(chemotherapy and radiotherapy) and surgery. 
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